thebench.bio #1 Ecosystem for the Bio-Tech Industry

Funding Daily Summary

Funding Daily Summary: What Happened on November 15, 2026

Oyster raises $60 million for tau-degrader research

The London startup will use the Series A-2 financing to advance a preclinical Alzheimer’s candidate and other programs.

  • Updated
  • Read from 1 article, 1 publication

Today in brief

Oyster Therapeutics secured $60 million in Series A-2 funding for its preclinical candidate, designed to degrade disease-linked tau.1

Also worth knowing

  • 4BIO Capital led the round, joined by Eli Lilly and other new and existing investors. CEO Rob Johnson said Oyster aims to take its tau degrader into clinical testing.1